Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma

Celia A. Kanashiro, Andrew V. Schally, Jozsef L. Varga, Brian Hammann, Gabor Halmos, Marta Zarandi

Research output: Contribution to journalArticle

17 Scopus citations


Effects of in vivo treatment with antagonists of growth hormone-releasing hormone (GHRH), JV-1-65 and MZ-J-7-110, and bombesin/gastrin-releasing peptide antagonist RC-3940-II, on the EGF receptor (EGFR) family, were investigated in H-69 SCLC. Tumors were analyzed by RT-PCR, immunoblotting and binding assays. Treatment with these analogs reduced the binding capacity of EGFR by 18-64%, and inhibited the mRNA expression for EGFR, HER-2 and -3 by 27-75.4, 17-26.3, and 13.8-46.6%, respectively. The antagonists also decreased the protein levels for EGFR by 21-34%, HER-2 by 36-68% and HER-3 by 43-49%. This is the first demonstration that antiproliferative effects of GHRH antagonists are associated with a downregulation of EGF/HER receptors.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalCancer letters
Issue number2
StatePublished - Aug 26 2005



  • Bombesin/GRP
  • Cancer therapy
  • EGFR
  • GHRH antagonists
  • GRP antagonist
  • HER

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this